Brief: Revance Therapeutics Q2 Product Revenue USD 65.328 Million
08/08/2024 21:05
Aug 08 (Reuters) - Revance Therapeutics Q2 operating expenses USD 99.905 million. * Q2 net income USD -37.473 million
Recent news on Revance Therapeutics
See all newsBrief: Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Brief: Crown Laboratories And Revance Amend A&R Merger Agreement
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Kratos, Forward Air, Bank stocks
U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup